| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 09/18/2003 | CA2476031A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| 09/18/2003 | CA2475738A1 Activated protein c formulations |
| 09/17/2003 | EP1344532A1 High molecular weight kininogen (HK) domain 5 derived peptides against thrombic diseases |
| 09/17/2003 | EP1344531A1 High molecular weight kininogen (HK) domain 5 derived peptides against thrombic diseases |
| 09/17/2003 | EP1343903A1 A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell |
| 09/17/2003 | EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases |
| 09/17/2003 | EP1343823A2 Antithrombotic von willebrand factor (vwf) collagen bridging blockers |
| 09/17/2003 | EP1343786A1 Novel pyridine-substituted pyrazolopyridine derivatives |
| 09/17/2003 | EP1343784A2 Urea substituted imidazoquinoline ethers |
| 09/17/2003 | EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 09/17/2003 | EP1343769A1 Benzoylpyridazines |
| 09/17/2003 | EP1343764A1 Urea and urethane derivatives as integrin inhibitors |
| 09/17/2003 | EP1343759A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 09/17/2003 | EP1343561A1 Serine protease inhibitors |
| 09/17/2003 | EP1343542A2 Carrier with solid fibrinogen and solid thrombin |
| 09/17/2003 | EP1343530A1 Oral pharmaceutical composition containing a block copolymer |
| 09/17/2003 | EP1343523A2 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings |
| 09/17/2003 | EP1343511A1 Shark meat extract |
| 09/17/2003 | EP1343505A1 Cxcr3 antagonists |
| 09/17/2003 | EP1343489A2 Sterile bicarbonate-free dialysis concentrate solutions |
| 09/17/2003 | EP1196411B1 Bradykinin b1 receptor antagonists |
| 09/17/2003 | EP1194428B1 Heteroaryl protease inhibitors and diagnostic imaging agents |
| 09/17/2003 | EP1133471B1 Hydrazine derivatives |
| 09/17/2003 | EP1104273B1 Indwelling heat exchange catheter |
| 09/17/2003 | EP1060242A4 Purified populations of stem cells |
| 09/17/2003 | EP0996446B1 Novel substituted imidazole compounds |
| 09/17/2003 | EP0724647A4 Nucleic acid ligands and improved methods for producing the same |
| 09/17/2003 | EP0571613B1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 09/17/2003 | CN1443197A Acid-modified arabinogalactan protein composition |
| 09/17/2003 | CN1443187A Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 09/17/2003 | CN1443184A 嘧啶衍生物 Pyrimidine derivatives |
| 09/17/2003 | CN1443173A Substituted imidazoles as TAFI a inhibitors |
| 09/17/2003 | CN1443167A Azacyclic compounds for use in treatment of 5-serotonin related diseases |
| 09/17/2003 | CN1443160A N-substituted-1-amino-1,1-dialkyl carboxylic acid derivatives |
| 09/17/2003 | CN1443155A Compounds to treat alzheimer's disease |
| 09/17/2003 | CN1443065A Pharmaceutical composition improved in peroral absorbability |
| 09/17/2003 | CN1442415A Preparation method of iso propylidene shikimic acid and its new use |
| 09/17/2003 | CN1442191A Synergistic safflower soluble suppository preparation |
| 09/17/2003 | CN1442158A Compound palm blood stanching oral liquid and its production process |
| 09/17/2003 | CN1442148A Daidzein drip pill and its preparation method |
| 09/17/2003 | CN1442139A Medicinal composition for treating inflammation |
| 09/17/2003 | CN1121402C Crystals of piperdine derivatives, intermediates for production of same, and process for producing the same |
| 09/17/2003 | CN1121224C Pharmaceutical composition comprising compound having anti Xa activity and platelet aggregation antagonist compound |
| 09/16/2003 | US6620840 Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 09/16/2003 | US6620807 Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| 09/16/2003 | US6620782 compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or |
| 09/16/2003 | CA2250274C Method and apparatus for preparing an acellular red blood cell substitute |
| 09/16/2003 | CA2249009C Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
| 09/16/2003 | CA2215695C .beta.-sheet mimetics and use thereof as protease inhibitors |
| 09/16/2003 | CA2078759C Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace |
| 09/15/2003 | CA2421490A1 Medicament against thrombotic diseases |
| 09/12/2003 | WO2003074711A1 Expression cassette for persistence of expression of a gene of interest in muscle cells |
| 09/12/2003 | WO2003074564A1 Novel hemepeptide |
| 09/12/2003 | WO2003074513A2 Indole amide derivatives and their use as glycogen phosphorylase inhibitors |
| 09/12/2003 | WO2003074512A1 Isoquinoline derivatives |
| 09/12/2003 | WO2003074489A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase |
| 09/12/2003 | WO2003074484A1 Indolamid derivatives which possess glycogenphosphorylase inhibitory activity |
| 09/12/2003 | WO2003074483A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| 09/12/2003 | WO2003074479A1 Semicarbazide derivatives and their use as antithrombotics |
| 09/12/2003 | WO2003074032A1 Oral administration form for difficulty soluble basic active ingredients which are applied orally |
| 09/12/2003 | WO2003074008A2 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | WO2003073986A2 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | WO2003073980A2 Recombinant protein c variants |
| 09/12/2003 | WO2003051333B1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 09/12/2003 | WO2003049784A3 Manual processing systems and methods for providing blood components conditioned for pathogen inactivation |
| 09/12/2003 | WO2003048081A3 Glycinamides as factor xa inhibitors |
| 09/12/2003 | WO2003037268A3 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/12/2003 | WO2003034987A3 Androgen receptor modulators and methods of use thereof |
| 09/12/2003 | WO2003006612A3 Production of transduced hematopoietic progenitor cells |
| 09/12/2003 | WO2002080979A3 Conjugate of hydroxyalkyl starch and an active agent |
| 09/12/2003 | WO2002058695A9 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 09/12/2003 | WO2001095785A3 Modulation of immune response and methods based thereon |
| 09/12/2003 | CA2478618A1 Isoquinoline derivatives |
| 09/12/2003 | CA2478528A1 Semicarbazide derivatives and the use thereof as antithrombotics |
| 09/12/2003 | CA2477876A1 Recombinant protein c variants |
| 09/12/2003 | CA2477874A1 Expression cassette for persistence of expression of a gene of interest in muscle cells |
| 09/12/2003 | CA2477717A1 Indolamid derivatives which possess glycogen phosphorylase inhibitory activity |
| 09/12/2003 | CA2477715A1 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient |
| 09/12/2003 | CA2477449A1 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | CA2477423A1 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/11/2003 | WO2003074056A1 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally |
| 09/11/2003 | US20030171579 N-benzyl-N'-phenylurea derivatives; inhibitors of the coagulation factors Xa and VIIa |
| 09/11/2003 | US20030171559 A colony-stimulating factor hybrid molecules, computer analyzing the three dimensional structure protein, crystallization of the protein |
| 09/11/2003 | US20030171548 Immunoreactive proteins where the percentage of immuno-reactive molecules as determined in a modified Lindmo-test is >81%; fermentation of culture of fluidized reactor; diagnosis of inflammatory and bone marrow displacing process |
| 09/11/2003 | US20030171541 Selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides; diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides |
| 09/11/2003 | US20030171539 Synthetic oligopeptide heparin-neutralizing agents including basic amino acids and a N-heterocyclic end group; low turbidity; side effects reduction; in vitro diagnosis; calculate the blood clotting time; assaying clotting cascade |
| 09/11/2003 | US20030171536 Solid phase synthesis by the condensation of three partial fragments being carried out between the amino acid positions Glycine 108 and Arg 109 and amino acid positions Gly 120 and Cys 121; cyclization; deblocking; side-effects reduction |
| 09/11/2003 | US20030171409 Novel delta dicarbonyl compounds and methods for using the same |
| 09/11/2003 | US20030171404 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 09/11/2003 | US20030171389 Anticancer agents; bone disorders; antiarthritic agents |
| 09/11/2003 | US20030171380 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| 09/11/2003 | US20030171373 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 09/11/2003 | US20030171337 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and |
| 09/11/2003 | US20030171331 Oxazolidinone cotherapy |
| 09/11/2003 | US20030171304 Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof |
| 09/11/2003 | US20030171273 DNA of SEQ ID NO:1 is provided that encodes the transcription factor BP1, which is believed to be a repressor of the beta -globin gene. A host cell that is transformed with a vector that contains the DNA may be used to produce BP1. |
| 09/11/2003 | US20030171267 Albumin fusion proteins |
| 09/11/2003 | US20030170811 Culturing a microorganism transformed with an expression vector comprising a gene encoding an amino acid sequence of a peptide-fused atriopeptin; use as antihypertensive diuretic agent |
| 09/11/2003 | US20030170331 Plant extract of the olea europaea as no-synthase inhibitor and uses |
| 09/11/2003 | US20030170287 Rapamycin or a rapamycin derivative having mTOR inhibiting properties |